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Methods: Levels of IL-18 was determined by ELISA in serum
from healthy individuals (n=31), HB-immune patients (n=13),
anti-HBe positive patients with HBV DNA levels below 104 (n=25)
or above 104 (n=20) copies/ml and HBeAg positive patients with
chronic hepatitis B (CHB) (n=14). HBV DNA was assessed by Cobas
Amplicor HBV Monitor TM test. IL-18 reactivity was monitored
longitudinally in comparison with the viremia in 15 CHB patients
treated with interferon-alpha.
Results: The serum levels of IL-18 was signiﬁcantly higher in anti-
HBeAg positive and HBeAg positive patients with CHB compared
with healthy individuals (p<0.05). In vivo, the longitudinal study
demonstrated a highly inverse correlation between the levels of
HBV DNA and the circulating concentrations of IL-18. Patients
with IFN alpha-induced reduction in HBV DNA levels exhibited
a signiﬁcant increase in measurable IL-18 reactivity (p<0.001)
which always peaked after the decrease of HBV DNA in serum.
Conclusions: The inverse correlation between the decrease of
HBV viremia and the increase of measurable circulatory levels
of IL-18 indicate a strong relationship between the control of
replication of HBV DNA and the production of IL-18 in CHB.
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In HBeAg positive chronic hepatitis B treatment, serum HBeAg
loss or serological conversion was primary endpoint and the most
important parameter of the efﬁcacy evaluation. But in the pa-
tients treatment with interferon and nucleoside analogues, the
change modules of serum HBV DNA, HBeAg and HBsAg contents
was difference between the two kinds of drugs. The aim of this
study was analyzing the correlation ships among serum HBV DNA,
HBeAg and HBsAg contents in HBsAg-positive chronic hepatitis B
patients treated with interferon.
There were 228 cases of HBeAg-positive patients, with serum HB-
sAg positive for more than 6 months, HBV DNA content >5.0×105
copies/ml and ALT level from 41 to 400 U/ml, enrolled in
this study. After enrolled, patients was treated with PEGASYS,
180mg, subcutaneous injection once weekly, for 48 weeks, and
with another 24 week follow. The serum HBV NDA, HBeAg and
HBsAg contents were examined at 0, 24 and 48 week and the end
of follow.
The serum HBV NDA, HBeAg and HBsAg baseline were lg
7.139±0.974 copies/ml, lg 2.486±0.926 S/CO and lg 4.139±0.756
IU/ml, respectively, and the correlation among them were sig-
niﬁcance (p<0.001), and at 24, 48 week on-treatment and the
end of follow, the correlation among them was signiﬁcance
also (p<0.001). After mixed-variable linear regression analysis
tested, at 48 week, the HBsAg clear could be predicted by the
levels of HBsAg baseline and its descend extent at 24 week, and
HBV DNA descend extent at 24 and 48 week, and the HBeAg
clear could be predicted by the levels of HBeAg baseline and its
descend extent at 24 week, and HBV DNA descend extent at 24
and 48 week.
In this study it was shown that during the course of interferon
therapy, there were correlation among HBV DNA, HBeAg and HB-
sAg contents and their changes, and it was important monitoring
the changes of them.
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Backgroud: To assess effects of combination of lamivudine plus
interferon-α for HBeAg positive chronic hepatitis B.
Methods: We included randomized trials of combination of
interferon-α plus lamivudine vs. lamivudine or interferon-α alone
in adult patients with HBeAg positive chronic hepatitis B. We
searched MEDLINE, EMBASE, and Cochrane and SCI database
(1980-2008), supplemented with reference lists and contact with
trial investigators. We used random-effect model to pool trials,
and employed a limited number of pre-speciﬁed variables to
explore sources of heterogeneity.
Results: Compared to interferon-α, combination therapy did
not improve HBeAg seroconversion (29.3% vs. 28.3%; RR1.05,
95%CI0.81 to 1.35) and combined virological response (19.9% vs.
12.9%; 1.52, 0.82 to 2.86), loss of HBV DNA (38.1% vs. 31.1%;
1.38, 1.03 to 1.84), and ALT normalization (40.0% vs. 36.8%; 1.13,
0.93 to 1.38) at the end of post-treatment follow-up. Compared
to lamivudine, combination therapy improved HBeAg seroconver-
sion (30.5% vs. 17.8%; 1.76, 1.29 to 2.42), loss of HBV DNA (32.5%
vs. 19.8%; 1.61, 1.29 to 2.02), combined virological response
(25.1% vs. 10.8%; 2.30, 1.70 to 3.12), and ALT normalization
(37.9% vs. 24.8%; 1.52, 1.25 to 1.84) at the end of follow-up.
Combination therapy reduced resistance to lamivudine at the
end of treatment (7.2% vs. 25.5%; 0.28, 0.19 to 0.40).
Conclusions: Combination therapy improves treatment effects
over lamivudine, but has no superior effects over interferon-α.
Given increased costs and adverse events, combination therapy
of lamivudine plus interferon-α is not recommended for routine
use.
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Background: Serum HBVRNA is detected during lamivudine ther-
apy, its pattern in sequential therapy of interferon and lamivu-
dine is unknown.
Methods: HBVDNA and RNA were quantiﬁed by reverse transcrip-
tion of HBV nucleic acid extract and real-time PCR in 10 patients
under lamivudine or entecavir, 6 under sequential interferon and
lamivudine, and 3 under short-term lamivudine.
